BioCardia, Inc. (OTCMKTS:BCDA) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry Into a Material Definitive Agreement.
On July 5, 2019, BioCardia, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Purchase Agreement”) with certain officers and directors and a principal stockholder of the Company (the “Purchasers”), to issue and sell convertible promissory notes (the “Notes”) in the aggregate principal amount of $625,000. The offers and sales of the Notes were made to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). Such offers and sales were made solely to qualified investors and was made without any form of general solicitation and with full access to any information requested by the investor regarding the Company or the securities offered. The proceeds will be used for general corporate purposes.
The Purchase Agreement includes customary representations, warranties and covenants by the Company, including negative covenants with respect the incurrence of indebtedness, the incurrence of liens and the disposition of assets, and customary closing conditions.
The foregoing does not purport to be a complete description of the Purchase Agreement and is qualified in its entirety by reference to the full text of such document, which is attached as Exhibits 10.1 to this Form 8-K and incorporated by reference herein.
On July 5, 2019, the Company issued $625,000 aggregate principal amount of Notes. The Notes will bear interest at 14% per annum, payable at maturity. The Notes mature on January 5, 2020, unless earlier repurchased by the Company or converted to their terms.
The Notes will be automatically converted into shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) and/or securities exercisable or convertible into Common Stock, as applicable, upon the closing of an offering of the Common Stock and/or securities exercisable or convertible into Common Stock in connection with the listing of shares of such common stock on a national securities exchange (a “Qualified Financing”) at a conversion price equal to 50% of the price to the public in such Qualified Financing. The Notes are also convertible at any time at the option of the holder into shares of the Common Stock at $8.00 per share, subject to adjustment upon stock dividend, stock split, combination of shares, reorganization, recapitalization, reclassification or other similar event.
If the Notes have not been converted into Common Stock and/or securities exercisable or convertible into Common Stock to a Qualified Financing within 45 calendar days after the original issuance date of the Notes, the Company will have the right to prepay the Notes in full in an amount equal to the outstanding principal amount thereof plus all unpaid interest that would otherwise be due at maturity.
The Notes provide for customary “events of default,” including, among others, upon: (i) non-payment of amounts due thereunder; (ii) non-compliance with covenants thereunder; (iii) breach of any representation or warranty made thereunder; and (iv) certain events of bankruptcy, insolvency or reorganization of the Company.
If such an event of default, other than an event of default described in clause (iv) above with respect to the Company, occurs and is continuing, a Majority in Interest of Holders (as defined in the Notes), by written notice to the Company, may declare all obligations under the Notes outstanding to be immediately due and payable. If an event of default described in clause (iv) above with respect to the Company occurs, all obligations under the Notes outstanding are to be immediately due and payable.
The Notes are senior unsecured obligations of the Company and will rank equal in right of payment to any of the Company’s unsecured, unsubordinated indebtedness.
The foregoing does not purport to be a complete description of the Form of Convertible Promissory Note and is qualified in its entirety by reference to the full text of such document, which is attached as Exhibit 4.1 to this Form 8-K and incorporated by reference herein.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information included in Item 1.01 of this Form 8-K is hereby incorporated by reference into this Item 2.03.
Item 3.02. Unregistered Sales of Equity Securities.
The information included in Item 1.01 of this Form 8-K is hereby incorporated by reference into this Item 3.02.
Item 9.01 Financial Statements and Exhibits.
BioCardia, Inc. Exhibit
EX-4.1 2 ex_149267.htm EXHIBIT 4.1 ex_149267.htm Exhibit 4.1 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,…
To view the full exhibit click
About BioCardia, Inc. (OTCMKTS:BCDA)
BioCardia, Inc., formerly Tiger X Medical, Inc., is a clinical-stage regenerative medicine company. The Company is engaged in developing therapeutics for cardiovascular diseases. The Company’s lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP). It focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure. The Company also offers CardiALLO Cell Therapy System (CardiALLO), an allogeneic off the shelf mesenchymal stem cell product candidate from other donors. It focuses on the Phase II trial for CardiALLO for the treatment of ischemic systolic heart failure. The Company focuses on various fields of autologous and allogeneic cell-based therapies to manage the lives of patients with cardiovascular conditions. CardiAMP is a therapeutic treatment that includes a companion diagnostic. It consists of a cell potency screening test, a point of care cell processing platform and a biotherapeutic delivery system.